Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $1.33M rose 5.3% year over year, behind the +19.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 16.6% from the prior quarter. Over 3 fiscal years it compounded at +13.1% a year.
Context
- Cost of revenue amounted to 12.7% of revenue in FY2025, up 3.9 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.3% toward the trailing-twelve-month pace of +19.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 6.57M USD
- Year-over-year change
- +16.9%
- 4-year CAGR
- +10.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.57M | +16.9% |
| FY2024 | 2024-12-31 | 5.63M | +6.5% |
| FY2023 | 2023-12-31 | 5.28M | +16.3% |
| FY2022 | 2022-12-31 | 4.54M | +3.0% |
| FY2021 | 2021-12-31 | 4.41M | — |
Cost of Revenue vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.4% is the 4th highest of 8, against a peer median of +8.0%.
- Cost of revenue amounts to 12.8% of revenue for OCUL, versus a peer median of 24.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.28B USD | +8.0% | +15.0% | 42.8% | |
| LTM Jun 2026 | $127.96M USD | +24.9% | +18.3% | 20.9% | |
| LTM Mar 2026 | $69.57M USD | +28.3% | +38.8% | 25.9% | |
| LTM Apr 2026 | $68.44M USD | -5.7% | -2.2% | 23.6% | |
| LTM Mar 2026 | CHF 15.07M CHF | — | — | 2989.4% | |
| LTM Mar 2026 | $6.64M USD | +19.4% | +13.1% | 12.8% | |
| LTM Mar 2026 | $1.79M USD | -52.4% | -37.2% | 23.5% | |
| LTM Mar 2026 | $1.54M USD | +977.1% | +54.6% | 460.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $612K USD | — | — | — |
| LTM Sep 2026 | $0 USD | -100.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding OCUL) | — | +8.0% | +16.6% | 24.7% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M |
| Cost of Revenue | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | 39.12M | 46.95M | 53.16M | 58.1M | 45.25M |
| Gross Margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Research & Development | 50.08M | 53.46M | 61.06M | 127.64M | 197.1M |
| Selling, General & Admin | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M |
| Operating Expenses | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| EBITDA | 2.54M | (61.91M) | (66.42M) | (176.14M) | (249.78M) |
| EBITDA Margin | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| Operating Income | (78.04M) | (78.65M) | (82.38M) | (171.78M) | (270.02M) |
| Operating Margin | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| Interest Income | 33K | 798K | 3.98M | 20.28M | 18.36M |
| Interest Expense | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M |
| Other Income / Expenses | 71.48M | 7.62M | 1.65M | (21.73M) | 4.08M |
| Income Before Tax | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Pre-Tax Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Net Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| EPS (Basic) | (1.05) | (1.04) | (1.09) | (1.22) | (1.42) |
| EPS (Diluted) | (0.98) | (0.97) | (1.02) | (1.22) | (1.42) |
| Weighted Avg Shares | 76.39M | 76.88M | 79.83M | 158.27M | 187.24M |
| Weighted Avg Shares (Diluted) | 82.16M | 82.64M | 85.6M | 158.27M | 187.24M |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.